 |
|
Researchers Identify Role of Gene in Tumor Development, Growth and Progression
November 23, 2009Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth.
According to Paul B. Fisher, M.Ph., Ph.D., professor and chair of the Department of Human and Molecular Genetics, director of the VCU Institute of Molecular Medicine in the VCU School of Medicine, and program leader of Cancer Molecular Genetics at the Massey Cancer Center, the team has shown that astrocyte elevated gene-1, AEG-1, a cancer promoting gene, is involved in both oncogenic transformation, which is the conversion of a normal cell to a cancer cell, and angiogenesis, which is the formation of new blood cells. Oncogenic transformation and angiogenesis are critical for tumor development, growth and progression to metastasis.
In the study published online the week of Nov. 16 in the Early Edition of the journal Proceedings of the National Academy of Sciences, researchers employing a series of molecular studies reported that the elevated expression of AEG-1 is involved with turning normal cells into cancer cells.
According to Fisher, when AEG-1 was expressed in normal immortal rat embryo fibroblast cells it converted these cells into transformed cells that induced rapidly growing aggressive cancers when injected into animals. AEG-1 expressing cells displayed enhanced expression of genes regulating blood vessel formation, thereby contributing to tumorigenicity. The team has further defined the pathways in target cells that are activated by AEG-1 and mediate its oncogenic and angiogenic inducing properties.
"Our goal is to understand the functions of a novel gene AEG-1 that plays an essential role in tumor progression, with potential to develop effective therapeutic approaches for multiple cancers through targeted inhibition of this novel molecule or its downstream regulated processes," said Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center.
"We believe it will pave the way for ameliorating the sufferings of scores of cancer patients by uncovering new and effective avenues for treatment," he said.
To expand the work on AEG-1, the VCU Department of Human and Molecular Genetics, Institute of Molecular Medicine and Massey Cancer Center recently received a National Cancer Institute grant totaling $1.6 million to study the AEG-1 gene in the context of malignant brain tumors such as glioblastoma multiforme, or GBM. According to Fisher, who is the primary investigator for the study, the work will extend the understanding of this gene and how it may serve as an oncogenic, or transforming gene.
"Cancer development and progression are multi-factor and multi-step processes that occur in a temporal manner. As mentioned above AEG-1 clearly has multiple roles in various steps of tumor progression, including tumor cell growth, insensitivity to growth-inhibitory signals, including chemotherapeutic agents, invasion, angiogenesis and metastasis," explained Fisher.
"In addition, AEG-1 has been known to have oncogenic roles in various cancers including glioma (CNS tumor), neuroblastoma, liver cancer, breast cancer, prostate cancer, lung cancer, and esophageal squamous cell carcinoma. These important correlations make this gene an intriguing molecule to study with potential to serve as a direct target for cancer therapy," he said.
The gene was discovered in 2002 in Fisher's laboratory while he was at the Columbia University College of Physicians and Surgeons in New York.
Fisher worked with a team that included VCU School of Medicine researchers Zao-zhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, M.B.B.S., Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; Hyun Yong Jeon, M.S., research assistant with the VCU Department of Human and Molecular Genetics; Luni Emdad, M.D., Ph.D., with the Mount Sinai School of Medicine in New York; and Habib Boukerche, Ph.D., a senior scientist with the University Lyon 1 in France.
Virginia Commonwealth University
According to Fisher, when AEG-1 was expressed in normal immortal rat embryo fibroblast cells it converted these cells into transformed cells that induced rapidly growing aggressive cancers when injected into animals. AEG-1 expressing cells displayed enhanced expression of genes regulating blood vessel formation, thereby contributing to tumorigenicity. The team has further defined the pathways in target cells that are activated by AEG-1 and mediate its oncogenic and angiogenic inducing properties.
"Our goal is to understand the functions of a novel gene AEG-1 that plays an essential role in tumor progression, with potential to develop effective therapeutic approaches for multiple cancers through targeted inhibition of this novel molecule or its downstream regulated processes," said Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center.
"We believe it will pave the way for ameliorating the sufferings of scores of cancer patients by uncovering new and effective avenues for treatment," he said.
To expand the work on AEG-1, the VCU Department of Human and Molecular Genetics, Institute of Molecular Medicine and Massey Cancer Center recently received a National Cancer Institute grant totaling $1.6 million to study the AEG-1 gene in the context of malignant brain tumors such as glioblastoma multiforme, or GBM. According to Fisher, who is the primary investigator for the study, the work will extend the understanding of this gene and how it may serve as an oncogenic, or transforming gene.
"Cancer development and progression are multi-factor and multi-step processes that occur in a temporal manner. As mentioned above AEG-1 clearly has multiple roles in various steps of tumor progression, including tumor cell growth, insensitivity to growth-inhibitory signals, including chemotherapeutic agents, invasion, angiogenesis and metastasis," explained Fisher.
"In addition, AEG-1 has been known to have oncogenic roles in various cancers including glioma (CNS tumor), neuroblastoma, liver cancer, breast cancer, prostate cancer, lung cancer, and esophageal squamous cell carcinoma. These important correlations make this gene an intriguing molecule to study with potential to serve as a direct target for cancer therapy," he said.
The gene was discovered in 2002 in Fisher's laboratory while he was at the Columbia University College of Physicians and Surgeons in New York.
Fisher worked with a team that included VCU School of Medicine researchers Zao-zhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, M.B.B.S., Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; Hyun Yong Jeon, M.S., research assistant with the VCU Department of Human and Molecular Genetics; Luni Emdad, M.D., Ph.D., with the Mount Sinai School of Medicine in New York; and Habib Boukerche, Ph.D., a senior scientist with the University Lyon 1 in France.
Virginia Commonwealth University
Tumor Development Current Events and Tumor Development News RSSNew cancer-fighting strategy focuses on signaling molecules
Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.
Mayo oral cancer study shows full tumor genome
Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors.
Mutations in different cells cooperate to set the stage for cancer
According to modern biology textbooks, a single genetic mutation is rarely enough to cause cancer. It is generally thought that cells must accumulate a series of mutations that work together to trigger tumor development.
Drug that modifies gene activity could help some older leukemia patients
Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.
More accurate diagnosis for leading cancer killer in children may be possible
Brain cancer is the leading cause of cancer death in children. Now a more accurate diagnosis of childhood brain cancers may soon be possible, according to researchers at Huntsman Cancer Institute (HCI) at the University of Utah. The information is published online today in the journal Cancer Research.
Targeting brain cancer cell metabolism may provide new treatment
Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of deadly glioblastomas that are driven by amplified signaling of the epidermal growth factor receptor (EGFR), according to a first-of-its-kind study by researchers at UCLA's Jonsson Comprehensive Cancer Center.
New aging studies improving vaccine efficacy for the elderly
A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects.
Study finds 231 new genes associated with head and neck cancer
A Henry Ford Hospital study has identified 231 new genes associated with head and neck cancer, one of the most deadly cancers responsible for 2.1 percent of all cancer deaths in the United States.
Short-term stress enhances anti-tumor activity in mice, Stanford study shows
Public speaking, anyone? Or maybe a big job interview? Dry your palms and take a deep, calming breath; there may be a silver lining.
Diesel exhaust is linked to cancer development via new blood vessel growth
Scientists here have demonstrated that the link between diesel fume exposure and cancer lies in how diesel exhaust induces the growth of new blood vessels that supply solid tumors. The researchers found that in both healthy and diseased animals, more new blood vessels sprouted in mice exposed to diesel exhaust than did in mice exposed to clean, filtered air. This suggests that previous illness isn't required to make humans susceptible to the damaging effects of the diesel exhaust.
More Tumor Development Current Events and Tumor Development News Articles
|
Application of Monoclonal Antibodies in Tumor Pathology (Developments in Oncology) by Dirk J. Ruiter (Editor), G.J. Fleuren (Editor), S.O. Warnaar (Editor) | |
 |
Immunocytochemistry in Tumor Diagnosis (Developments in Oncology) by Jose Russo (Editor) |
![2-AAF-induced tumor development in nucleotide excision repair-deficient mice is associated with a defect in global genome repair but not with transcription coupled repair [An article from: DNA Repair]](http://ecx.images-amazon.com/images/I/51FZ3K9Y7XL._SL160_.jpg) |
2-AAF-induced tumor development in nucleotide excision repair-deficient mice is associated with a defect in global genome repair but not with transcription coupled repair [An article from: DNA Repair] by E.M. Hoogervorst (Author), C.Th.M.v. Oostrom (Author), R.B. Beems (Author), B (Author) This digital document is a journal article from DNA Repair, published by Elsevier in 2005. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: The nucleotide excision repair (NER) pathway comprises two sub-pathways, transcription coupled repair (TCR) and global genome repair (GGR). To establish the importance of these separate sub-pathways in tumor suppression, we exposed mice deficient for either TCR (Csb), GGR (Xpc) or both (Xpa) to 300ppm 2-acetylaminofluorene (in feed, ad libitum) in a unique comparative exposure experiment. We found that cancer proneness was directly linked to a defect in the GGR pathway of NER as both Xpa and Xpc mice developed... |
|
Modification of Tumor Development in Rodents (Progress in Experimental Tumor Research) by Nobuyuki Ito (Other Contributor) Human cancer is now generally accepted as being primarily the result of a multitude of interacting environmental factors. This study offers coverage of the ability of exogenous influences to modify tumourigenesis in the organs most often involved in cancer. The first theoretical section highlights the principles now thought to underlie neoplasia in rodents and how they can be applied to in vivo risk assessment. In the second section, experienced researchers discuss the modification of tumour development in the gastrointestinal tract, liver, pancreas, lung, urinary bladder, breast and skin. Both endogenous and exogenous influences and their possible interactions are considered, with emphasis placed on dietary and other factors relevant to the human situation. | |
|
Familial Brain Tumors: A Commented Register (Developments in Oncology) by C.C. Tijssen (Author), M.R. Halprin (Author), L.J. Endtz (Author) | |
 |
The Rat as Animal Model in Breast Cancer Research: A histopathological study of radiation- and hormone-induced rat mammary tumors (Developments in Oncology) by Matthew J. van Zwieten (Author) |
 |
Diagnosis and Management of Malignant Solid Tumors in Infants and Children (Developments in Oncology) by Daniel M. Green (Author) |
|
Comparative Aspects of Tumor Development (Cancer Growth and Progression) by Hans E. Kaiser (Editor) | |
 |
Relevance of Tumor Models for Anticancer Drug Development (Contributions to Oncology/Beitrage Zur Onkologie) by Heinz-Herbert Fiebig (Editor) |
|
Inhibition of Tumor Induction and Development by Zedeck (Author) |
| © 2010 BrightSurf.com |